Evidence map›Paper›PMID 32488657›Full record

ReviewAdvances in therapy2020

Papillary Thyroid Cancer-Aggressive Variants and Impact on Management: A Narrative Review.

Andrés Coca-Pelaz, Jatin P Shah, Juan C Hernandez-Prera, Ronald A Ghossein, Juan P Rodrigo, Dana M Hartl, Kerry D Olsen, Ashok R Shaha, Mark Zafereo, Carlos Suarez and 13 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Advances in therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 167 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
167citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

167 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. mBiochemical genetics · 2026
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Impact of Subtype Variability on Clinical Features in Papillary Thyroid Cancer.The Journal of clinical endocrinology and metabolism · 2026
    Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

107 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Andrés Coca-PelazDepartment of Otolaryngology, Hospital Universitario Central de Asturias-University of Oviedo, Oviedo, Asturias, Spain. acocapelaz@yahoo.es.ORCID http://orcid.org/0000-0003-1363-8559
Jatin P ShahHead and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Juan C Hernandez-PreraDepartment of Pathology, Moffitt Cancer Center, Tampa, FL, USA.
Ronald A GhosseinDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Juan P RodrigoDepartment of Otolaryngology, Hospital Universitario Central de Asturias-University of Oviedo, Oviedo, Asturias, Spain.
Dana M HartlDivision of Surgical Oncology, Gustave Roussy Cancer Center and Paris-Sud University, Villejuif Cedex, Paris, France.
Kerry D OlsenDepartment of Otorhinolaryngology, Mayo Clinic, Rochester, MN, USA.
Ashok R ShahaHead and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Mark ZafereoDivision of Surgery, Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Carlos SuarezInstituto de Investigación Sanitaria del Principado de Asturias, IUOPA, CIBERONC, Oviedo, Asturias, Spain.
Iain J NixonDepartment of Surgery and Otolaryngology, Head and Neck Surgery, Edinburgh University, Edinburgh, Scotland, UK.
Gregory W RandolphMassachusetts Eye and Ear Infirmary, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Antti A MäkitieDepartment of Otorhinolaryngology, Head and Neck Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Luiz P KowalskiHead and Neck Surgery and Otorhinolaryngology Department, A C Camargo Cancer Center, São Paulo, Brazil.
Vincent Vander PoortenSection Head and Neck Oncology, Otorhinolaryngology-Head and Neck Surgery and Department of Oncology, University Hospitals Leuven, KU Leuven, Louvain, Belgium.
Alvaro SanabriaDepartment of Surgery, School of Medicine, Universidad de Antioquia/Hospital Universitario San Vicente Fundación-CEXCA Centro de Excelencia en Enfermedades de Cabeza y Cuello, Medellín, Colombia.
Orlando Guntinas-LichiusDepartment of Otorhinolaryngology, Institute of Phoniatry/Pedaudiology, Jena University Hospital, Jena, Germany.
Ricard SimoHead and Neck Cancer Unit, Guy's and St Thomas' Hospital NHS Foundation Trust London, London, UK.
Peter ZbärenDepartment of Otorhinolaryngology-Head and Neck Surgery, University Hospital, Berne, Switzerland.
Peter AngelosDepartment of Surgery, University of Chicago Medical Center, Chicago, IL, USA.
Avi KhafifHead and Neck Surgery and Oncology Unit, A.R.M. Center for Advanced Otolaryngology Head and Neck Surgery, Assuta Medical Center, Tel Aviv, Israel.
Alessandra RinaldoUniversity of Udine School of Medicine, Udine, Italy.
Alfio FerlitoCoordinator of the International Head and Neck Scientific Group, Padua, Italy.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

introductionAggressive variants of papillary thyroid cancer (PTC) have been described with increasing frequency. These variants include diffuse sclerosing variant, tall cell variant, columnar cell variant, solid variant, and hobnail variant.

methodsWe have performed a review of the more aggressive variants of PTC with respect to main characteristics, histological and molecular features, and the consequences that the knowledge of these variants should have in the treatment of the patients.

resultsAt the present time, we do not know the prognostic value of these aggressive PTC variants. The extent of the surgical treatment and adjuvant therapy necessary should be decided on the basis of the extent of the tumor at presentation and the opinion of experienced clinicians.

conclusionThese aggressive variants should be known by clinicians, to avoid underdiagnosis, and treated according to the latest recommendations in the literature.

Indexed as

Genetic VariationAdultAgedAged, 80 and overCarcinoma, PapillaryFemaleHumansMaleMiddle AgedThyroid Cancer, PapillaryThyroid NeoplasmsAggressive variants papillary thyroid cancerColumnar cell variantDiffuse sclerosis variantHobnail variantSolid variantTall cell variant

Identifiers

PMID32488657
PMCPMC7467416

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.